It’s taken years for Amarin’s fish-oil derivative Vascepa to prove itself as a game-changing treatment for cardiovascular disease. After a “landmark” outcomes trial last year and a hotly anticipated FDA advisory meeting Thursday, Vascepa may now have its ticket to the
read moreContinuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation with plans for a $120 million addition to its facilities in Texas. More: Fujifilm adding 0M facility to its gene therapy operations in
read moreWith a potential approval next year in the up-and-coming NASH field, Intercept is getting into gear. The company is nearly tripling its sales force to 150, working with contract sales reps and talking with payers with the FDA’s permission. More:
read moreMore: Manufacturing News of Note—Samsung Bioepis, Biogen add to biosimilars; Boehringer Ingelheim to add 105 jobs in Puerto Rico Source: fierce
read moreCompetition in the multiple sclerosis field has stepped up significantly, thanks to several recent drug launches. But in that fray, Merck KGaA’s Mavenclad can be counted as one successful rollout—at least so far—as its third-quarter sales offset losses for the
read moreThe organisation updates its MS Guideline to state that Sativex should be offered to treat spasticity in people with the disorder. More: NICE ‘OK’ for Sativex in MS Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals